Tsai JT |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=1 ------>paper_class2=1 ------>vol=3 ------>confirm_bywho=None ------>insert_bywho=enochlai49 ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=61 ------>medlineContent= ------>unit=000 ------>insert_date=20090314 ------>iam=2 ------>update_date=None ------>author=??? ------>change_event=1 ------>ISSN= ------>authors_c= ------>score=-3 ------>journal_name=Therapeut Radiol Oncol ------>paper_name=Prognostic parameters in malignant glimas ------>confirm_date=None ------>tch_id=083041 ------>pmid=19815537 ------>page1=49 ------>fullAbstract=OBJECTIVE: The clinical course of gastrointestinal stromal tumor (GIST) spans a wide spectrum from a curable disorder to a highly malignant disease that leads to metastasis and death. To develop prognostic modalities for GIST patients, we developed a mouse monoclonal antibody against pfetin, the prognostic value of which has been previously reported. METHODS: The reactivity of the monoclonal antibody against pfetin was examined by western blotting and immunohistochemistry. RESULTS: Western blotting demonstrated that the monoclonal antibody was specific to pfetin. The immunohistochemical study demonstrated that the 5-year disease-free survival rate was 93.2% and 94.5% for GIST patients with pfetin-positive tumors and 70.0% and 80.7% for those with pfetin-negative tumors in the 159 cases from the National Cancer Center Hospital (P < 0.0001) and in the 100 cases from Niigata University Medical and Dental Hospital (P < 0.0001), respectively. Uni- and multivariate analyses revealed that pfetin expression was a powerful prognostic factor among the clinico-pathological parameters examined. CONCLUSIONS: These results establish pfetin as a practical prognostic marker for GIST patients after surgery. Pfetin may also present a novel therapeutic target to prevent recurrence of GIST. ------>tmu_sno=None ------>sno=21533 ------>authors2=Lai YL ------>authors3=Yeh CY ------>authors4=Chen YJ ------>authors5=Shau WY ------>authors6=Chung CH, Chang KH ------>authors6_c= ------>authors=Tsai JT ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=NULL ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=1996 ------>submit_flag=None ------>publish_month=1 |